CJC-1295 side effects: what's measured, what's inferred, and the DAC concern

CJC-1295 is a synthetic, long-acting analog of growth-hormone-releasing hormone (GHRH), usually sold in the “DAC” form that binds albumin and stretches its half-life to days. It is not an FDA-approved drug, and the honest problem with cataloguing its side effects is that almost nobody has studied them properly. What follows separates the little that is measured in humans from the larger set of effects that are inferred from the biology of a raised GH/IGF-1 axis. For the efficacy side of the ledger, see the ipamorelin & CJC-1295 evidence review.

What human data actually exist

The controlled human record is essentially one small study. Teichman and colleagues gave CJC-1295 to healthy adults in ascending-dose, placebo-controlled trials and reported that it produced sustained, dose-dependent rises in GH and IGF-1, with no serious adverse reactions and a drug that was “relatively well tolerated.”^[1] That is reassuring as far as it goes — but it was a pharmacokinetic and pharmacodynamic study in a few dozen people, not a trial powered or designed to detect harm, and it says nothing about months or years of use. So the correct starting posture is not “it looks safe” but “it has barely been studied.”

The commonly reported, milder effects

The effects most often described with GHRH-class peptides are local and vascular: injection-site reactions (redness, itching, a small welt), transient flushing, and headache. These are consistent with the pharmacology of a subcutaneously injected vasoactive peptide, and they map onto what is documented for approved GHRH analogs. Because CJC-1295 itself has not been characterized for these specifically beyond the “well tolerated” summary above, the better-described sibling profile lives on the sermorelin side-effects page — sermorelin being an approved, shorter-acting GHRH analog whose adverse-event profile is far better documented.

Water retention, tingling, and glucose: the GH-excess signature

The effects people worry about most are not unique to CJC-1295 — they are the classic consequences of pushing the GH/IGF-1 axis, and they are best characterized in states of chronic GH excess. Sustained GH promotes sodium and fluid retention, producing soft-tissue swelling and edema; the same soft-tissue expansion around the wrist is a recognized cause of carpal tunnel syndrome, which is the mechanism behind the tingling and numbness research users describe.^[4] And GH is a counter-regulatory hormone: sustained elevation antagonizes insulin, raising the risk of insulin resistance and impaired glucose tolerance.^[3] None of these has been measured in CJC-1295 users specifically — the point is that the drug’s entire mechanism is to raise the exact hormones that, in excess, drive these effects.

The DAC-specific concern: a raised trough, not a pulse

Here is the concern that is genuinely specific to the long-acting DAC form. Natural GH is secreted in sharp pulses that fall back to a near-zero baseline between peaks, and that pulsatile pattern is thought to matter for the hormone’s normal physiology. When Ionescu and Frohman gave a single CJC-1295 injection and sampled GH overnight, the pulses were preserved — their frequency and magnitude were unchanged — but basal (trough) GH rose roughly 7.5-fold, and it was that raised interpulse floor that drove the increase in mean GH and IGF-1.^[2] In other words, the DAC version does not so much amplify the peaks as lift the valleys, shifting a naturally pulsatile signal toward a more continuous elevation.^[1] Whether that chronically raised baseline carries the same long-term risk as GH excess is exactly the question no study of this peptide has answered.

The supply problem sits on top of all of this

Everything above assumes the vial contains pure CJC-1295 at the stated amount. It usually cannot be assumed. These peptides are sold almost entirely as “research-use-only”products made outside pharmaceutical manufacturing standards, which means the purity, sterility, actual dose, and even the identity of the contents are unverified. Contaminants, endotoxin, incorrect peptides, and inconsistent concentration are all realistic — and those risks are entirely separate from, and additional to, the peptide’s own pharmacology. A clean safety story about the molecule would not rescue a contaminated vial. This is why no discussion of dose belongs here; if you want to see how that same caution frames the numbers, the CJC-1295 & ipamorelin dosage page treats it the same way.

How this differs from ipamorelin

CJC-1295 and ipamorelin are frequently stacked but act at different points. Ipamorelin is a selective ghrelin-mimetic secretagogue that triggers a short GH pulse; CJC-1295 is the GHRH analog whose DAC form gives the sustained, trough-raising exposure described above. That difference matters for side effects: the DAC’s prolonged, non-pulsatile elevation is the concern unique to CJC-1295, whereas ipamorelin’s effects have their own profile — covered on the ipamorelin side-effects page.

The honest bottom line

CJC-1295’s side-effect profile is mostly a set of well-founded predictions, not a measured record. One small human study found it relatively well tolerated with no serious reactions;^[1] the fluid retention, carpal-tunnel-like tingling, and glucose effects are inferred from what sustained GH/IGF-1 excess reliably does;^[3][4] and the DAC form’s signature move is to raise the between-pulse GH floor rather than preserve the natural low trough.^[2] Layer on an unregulated supply chain of unknown purity, and the appropriate stance is caution and a clinician — not a stack assembled from a forum.